Medicare Enrolled

Dr. Zinoviy Abelev, MD

Endocrinology · Long Island City, NY
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
3711 QUEENS BLVD, Long Island City, NY 11101
7183615100
In practice since 2008 (17 years)
NPI: 1891941613 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Abelev from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abelev? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Abelev

Dr. Zinoviy Abelev is an endocrinology specialist in Long Island City, NY, with 17 years of NPI registration. Based on federal Medicare data, Dr. Abelev performed 5,669 Medicare services across 1,360 unique beneficiaries.

Between the years covered by Open Payments, Dr. Abelev received a total of $4,021 from 23 pharmaceutical and/or device companies across 80 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Abelev is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice ▲ Top 13% volume in NY $4,021 industry payments

Medicare Practice Summary

Medicare Utilization ↗
5,669
Medicare services
Top 13% in NY for endocrinology
1,360
Unique beneficiaries
$32
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~333 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 2,940 $19 $70
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
833 $105 $689
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
581 $8 $38
Blood glucose test using hand-held instrument
A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels.
579 $3 $14
Continuous glucose monitoring with interpretation
This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results.
389 $29 $189
Diabetes self-management training, individual
Individualized education and training for managing diabetes, billed per 30-minute session.
121 $46 $296
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
86 $13 $115
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
57 $76 $494
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
40 $148 $917
Hemoglobin A1c test (diabetes monitoring)
A blood test that measures your average blood sugar levels over the past two to three months.
16 $10 $62
Continuous glucose monitoring, sensor under skin
This procedure involves continuous monitoring of blood sugar levels in tissue fluid using a sensor placed under the skin with provider-supplied equipment.
15 $142 $868
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
12 $111 $979
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$4,021
Total received (2018-2024)
Avg $574/year across 7 years
Top 30% in NY for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
23
Companies
80
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,921 (97.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (2.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$545
2023
$830
2022
$583
2021
$580
2020
$139
2019
$143
2018
$1,202

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Sekisui Diagnostics, LLC
$315
Insulet Corporation
$125
Novo Nordisk Inc
$62
BETA BIONICS, INC.
$42
Top 3 companies account for 92.3% of 2024 payments
All-time payments by company (2018-2024) ›
Sekisui Diagnostics, LLC
$910
Novo Nordisk Inc
$376
Amgen Inc.
$356
Abbott Laboratories
$301
Dexcom, Inc.
$271
Boehringer Ingelheim Pharmaceuticals, Inc.
$259
DEXCOM, INC.
$244
Nevro Corp.
$185
Insulet Corporation
$160
AstraZeneca Pharmaceuticals LP
$144
Corcept Therapeutics
$125
Lilly USA, LLC
$110
Ipsen Biopharmaceuticals, Inc
$100
SANOFI-AVENTIS U.S. LLC
$95
CeQur Corporation
$82
MannKind Corporation
$80
Merck Sharp & Dohme Corporation
$76
BETA BIONICS, INC.
$42
Davol Inc.
$32
Tandem Diabetes Care, Inc.
$25
Ascensia Diabetes Care Us Inc.
$22
AbbVie, Inc.
$16
Radius Health, Inc.
$11
Top 3 companies account for 40.8% of all-time payments
Associated products mentioned in payments ›
AFREZZA · BD MAX · BYDUREON · CeQur Simplicity · DEXCOM G6 TRANSMITTER · DEXCOM G7 GSS (161) · Dexcom G6 Transmitter · EVENITY · FARXIGA · FREESTYLE LIBRE 2 · FreeStyle Lite system · Increlex · JANUVIA · JARDIANCE · Korlym · MOUNJARO · Omnia · Omnipod · Ozempic · Prolia · Somatuline Depot · Synthroid · TOUJEO · TRADJENTA · TZIELD · Tymlos · Victoza · iLet Bionic Pancreas · t-slim insulin pump
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for an endocrinology specialist in Long Island City?
Compare endocrinologists in the Long Island City area by procedure volume, costs, and industry payment transparency.
Browse endocrinologists nearby

Geographic Context

Endocrinologists within 10 mi
677
Per 100K population
29.1
County median income
$84,961
Nearest hospital
NEW YORK-PRESBYTERIAN HOSPITAL
1.7 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Abelev is a clinical cardiology specialist, with above-average Medicare volume (top 13% in NY), with low-engagement industry engagement, with 17 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Abelev experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Abelev performed 2,940 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Abelev receive payments from pharmaceutical companies?
Yes. Dr. Abelev received a total of $4,021 from 23 companies across 80 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abelev's costs compare to other endocrinologists in Long Island City?
Dr. Abelev's average Medicare payment per service is $32. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abelev) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →